Literature DB >> 10752763

Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetil.

M Chandra1, M Susin, C Abitbol.   

Abstract

We report a 21-year-old male with childhood-onset familial nephrotic syndrome and frequent relapses who manifested toxicity or treatment resistance to corticosteroids, cyclophosphamide, cyclosporin-A, and tacrolimus. Monotherapy with mycophenolate mofetil (MMF) resulted in maintenance of clinical remission for 14 months without noticeable toxicity, while allowing resolution of steroid-induced side effects. Our observation suggests that MMF may be useful in maintaining remission in nephrotic patients who manifest toxicity to standard immunosuppressive agents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10752763     DOI: 10.1007/s004670050047

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  11 in total

1.  Effective tacrolimus treatment in a child suffering from severe nephrotic syndrome.

Authors:  Marco Pennesi; Ambra Gagliardo; Silvia Minisini
Journal:  Pediatr Nephrol       Date:  2003-04-05       Impact factor: 3.714

Review 2.  Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions.

Authors:  Asha Moudgil; Arvind Bagga; Stanley C Jordan
Journal:  Pediatr Nephrol       Date:  2005-06-24       Impact factor: 3.714

3.  Vincristine treatment in steroid-dependent nephrotic syndrome.

Authors:  Joshua Yehuda Kausman; Lei Yin; Colin Lindsay Jones; Lillian Johnstone; Harley Robert Powell
Journal:  Pediatr Nephrol       Date:  2005-06-24       Impact factor: 3.714

4.  Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome.

Authors:  S Mendizábal; I Zamora; O Berbel; M J Sanahuja; J Fuentes; J Simon
Journal:  Pediatr Nephrol       Date:  2005-05-13       Impact factor: 3.714

Review 5.  The management of idiopathic nephrotic syndrome in children.

Authors:  Elisabeth Hodson
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

6.  Steroid-resistant nephrotic syndrome: long-term evolution after sequential therapy.

Authors:  Antonia Peña; Juan Bravo; Marta Melgosa; Carlota Fernandez; Carmen Meseguer; Laura Espinosa; Angel Alonso; M Luz Picazo; Mercedes Navarro
Journal:  Pediatr Nephrol       Date:  2007-09-18       Impact factor: 3.714

7.  Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome.

Authors:  Zhihui Li; Cuirong Duan; Jinhua He; Tianhui Wu; Mai Xun; Yi Zhang; Yan Yin
Journal:  Pediatr Nephrol       Date:  2009-12-02       Impact factor: 3.714

8.  Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy.

Authors:  Kerstin Benz; Jörg Dötsch; Wolfgang Rascher; Daniel Stachel
Journal:  Pediatr Nephrol       Date:  2004-04-08       Impact factor: 3.714

9.  Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome.

Authors:  Gina-Marie Barletta; William E Smoyer; Timothy E Bunchman; Joseph T Flynn; David B Kershaw
Journal:  Pediatr Nephrol       Date:  2003-05-28       Impact factor: 3.714

10.  Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil.

Authors:  Jutta Gellermann; Uwe Querfeld
Journal:  Pediatr Nephrol       Date:  2004-01       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.